



# Electronic Information Disclosure Statement

## TRPM-2 Antisense Therapy Using an Oligonucleotide Having 2'-O-(2-methoxyethyl) modifications

Application:



10/080794

Confirmation:

2924

Applicant(s):

Martin Gleave

Docket Number:

UBC.P-020-3

Group Art Unit:

1632

Examiner:

search string:

( 6383808 ).pn.

### US Patent Documents

**Note:** Applicant is not required to submit a paper copy of cited US Patent Documents

init	Citation No.	Patent Number	Date	Bar Code	Patentee	Class	Subclass
160	P01	6383808	2002-05-07		Monia et al.	435	375

### Signature

Examiner Name	Date
	10/23/2004



ATTORNEY DOCKET NO. UBC.P-020-3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
JUN 26 2003  
TECH CENTER 1600/2900

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

Application No: 10/080,794  
Filing Date: February 22, 2002  
First Named Inventor: Gleave, et al.  
Confirmation No.: 2924  
Group Art Unit: 1635  
Examiner Name: LaCourciere, Karen A.  
Attorney Docket No.: UBC.P-020-3

**FOREIGN PATENT DOCUMENTS**

Examiner's Initials	office	Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages where relevant passages appear
<i>Hae</i>	WO	00/49937 A2	The University of British Columbia	Aug. 31, 2000	

This Information Disclosure Citation List is being submitted as a substitute for Form PTO-1449. The Examiner is requested to place his or her initials on the lines adjacent to the citations to indicate that the reference has been considered. The Examiner is further requested to fill in his or her name and the date the information was considered in blocks at the bottom of this substitute for Form PTO-1449.

Examiner: *Karen A. LaCourciere* Date Considered: *10/23/2004*



RECEIVED

MAR 31 2003

# 7 / Suppl.  
I.D.S

Application No.: 10/080,794  
Applicant: Gleave, et al.  
Filing Date: 02/22/2002  
Conf. No.: 2924  
Title: TRPM-2 Antisense Therapy  
Attorney Docket No.:  
UBC.P-020-3

Substitute for form 1449

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

TECH CENTER 1800/2000

Page 1 of 2

## U.S. PATENT DOCUMENTS

Examiners Initials	U S Patent No.	Name of Persons or applicant	Date of Publication of Cited Document
HCC	5,789,389	Tarasewicz et al.	08/04/1998
HCC	6,335,194 B1	Bennett et al.	01/01/2002

## FOREIGN PATENT DOCUMENTS

Examiners Initials	Patent No.	Name of Persons or applicant	Date of Publication of Cited Document
HCC	WO 01/46455 A2	Yale University	06/28/2001

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	
HCC	Nör et al.; Up-Regulation of Bcl-2 in Microvascular Endothelial Cells Enhances Intratumoral Angiogenesis and Accelerates Tumor Growth; Cancer Research; Vol. 61; March 1, 2001; 2183-2188.
	Kirby et al.; Bartonella-Associated Endothelial Proliferation Depends on Inhibition of Apoptosis; PNAS; Vol. 99, No. 7; April 2, 2002; 4656-4661.
	Cox et al.; Angiogenesis and Non-Small Cell Lung Cancer; Lung Cancer; Vol. 27, 2000; 81-100.
	Tran et al.; A Role for Survivin in Chemoresistance of Endothelial Cells Mediated by VEGF; PNAS; Vol. 99, No. 7; April 2, 2002; 4349-4354.
	Nör et al.; Engineering and Characterization of Functional Human Microvessels in Immunodeficient Mice; Laboratory Investigation; Vol. 81, No.4; April 2001; 453-463.
	Boral et al.; Clinical Evaluation of Biologically Targeted Drugs: Obstacles and Opportunities; Cancer Chemother Pharmacol; Vol. 42; 1998; S3-S21.

RECEIVED

MAR 31 2003

Substitute for form 1449

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT




Application No.: 10/080,794  
Applicant: Gleave, et al. TECH CENTER 1800/2900  
Filing Date: 02/22/2002  
Conf. No.: 2924  
Title: TRPM-2 Antisense Therapy  
Attorney Docket No.:  
UBC.P-020-3

Page 2 of 2

Hec	Zwain et al.; Clusterin Protects Granulosa Cells from Apoptotic Cell Death During Follicular Atresia; Experimental Cell Research; Vol. 257; 2000; 101-110.
Hec	Lee et al.; In Vitro Models of Prostate Apoptosis: Clusterin as an Antiapoptotic Mediator; The Prostate Supplement; Vol. 9; 2000; 21-24.
Hec	Genta Incorporated; New Data Reaffirm Genta's Molecular Target as Critical Factor for Enhancing Anticancer Treatment; <a href="http://www.genta.com">www.genta.com</a> ; 2001.

This Information Disclosure Citation List is being submitted as a substitute for Form PTO-1449. The Examiner is requested to place his or her initials on the lines adjacent to the citations to indicate that the reference has been considered. The Examiner is further requested to fill in his or her name and the date the information was considered in blocks at the bottom of this substitute for Form PTO-1449.

  
Examiner Signature

10/23/2004  
Date Considered